Unity Biotechnology Inc

-0.06 (-2.64%)
Products, Regulatory

UNITY Biotechnology Inc Announces Positive 12-Week Data From Phase 1 Clinical Trial Of UBX1325 In Advanced Vascular Eye Disease

Published: 10/05/2021 11:33 GMT
Unity Biotechnology Inc (UBX) - Unity Biotechnology Announces Positive 12-week Data From Phase 1 Clinical Trial of Ubx1325 in Advanced Vascular Eye Disease.
Unity Biotechnology Inc - Evidence of Improvement in Vision and Retinal Structure in Patients With Dme and Amd Sustained Through 12 Weeks.
Unity Biotechnology Inc - Sustained Responses Following Single Treatment With Ubx1325 Support Durability of Senolytic Therapeutic Approach.
Unity Biotechnology Inc - Study Remains on Track With 24-week Data Expected Before End of Year.
Unity Biotechnology - There Were No Dose-limiting Toxicities Observed, With Two Nonserious, Nondrug-related Adverse Events Reported Through 12 Weeks.